OncoMatch/Clinical Trials/NCT02526368
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Is NCT02526368 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies multiple treatments including Hyperpolarized 13C-Pyruvate and Hyperpolarized 13C,15N2-urea for prostate cancer.
Treatment: Hyperpolarized 13C-Pyruvate · Hyperpolarized 13C,15N2-urea — This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: for cohort a, prior 5-alpha reductase inhibitor allowed if discontinued ≥1 month before entry; for cohort b, prior 5-alpha reductase inhibitor allowed if discontinued ≥14 days before mri/mrsi
Cannot have received: cryosurgery for prostate cancer
Cannot have received: surgery for prostate cancer
Cannot have received: prostatic or pelvic radiotherapy
Exception: for cohort b, hifu focal therapy is allowed
Cannot have received: transurethral prostatic resection (turp)
Lab requirements
Kidney function
patients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal function.
Cardiac function
congestive heart failure or new york heart association (nyha) status >= 2. a history of clinically significant electrocardiography (ekg) abnormalities, including qt prolongation, a family history of prolonged qt interval syndrome, or myocardial infarction (mi) within 6 months of study entry; patients with rate-controlled atrial fibrillation/flutter will be allowed on study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02526368 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy, cryosurgery for prostate cancer, surgery for prostate cancer disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages